ACIG

37.3631.58%

AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology.

The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladder cancer.

FDA And EU Clear Klygefa For Generalized Myasthenia Gravis

Monday, the U.S. Food and Drug Administration and EU authorities approved Klygefa (gefurulimab) from Alexion, AstraZeneca Rare Disease, for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).

In the EU, regulators cleared the therapy as an add-on to standard treatment.

Read Also: Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer…'

Klygefa acts as the first and only dual-binding nanobody C5 inhibitor, allowing patients to self-administer a once-weekly subcutaneous injection via an autoinjector.

Pivotal PREVAIL Phase 3 trial results backed both approvals, showing Klygefa improved Myasthenia Gravis Activities of Daily Living (MG-ADL) total scores at week 26 over placebo (-1.6 difference; p<0.0001), with clinical gains starting by week one.

Regulators in China and additional nations currently review PREVAIL submissions.

FDA Approves Perioperative Imfinzi Regimen For Bladder Cancer

Friday, the FDA granted Priority Review approval to AstraZeneca’s Imfinzi (durvalumab) plus enfortumab vedotin (EV) before radical cystectomy, followed by Imfinzi monotherapy after bladder removal, for adults with muscle-invasive bladder cancer (MIBC) who refuse or cannot take cisplatin-based chemotherapy.

Roughly 16,000 U.S. patients will undergo MIBC treatment in 2026, and up to 50% cannot tolerate cisplatin due to kidney impairment or comorbidities.

In the VOLGA Phase 3 trial, which researchers presented at the 2026 ESMO Congress and published in The New England Journal of Medicine, the perioperative regimen cut progression, recurrence, missed surgery, or death risk by 49% versus surgery with or without approved adjuvant therapy (HR 0.51; p<0.0001).

The regimen also lowered death risk by 42% (HR 0.58; p=0.0027), keeping 78% of patients alive at two years versus 69%, and 64% event-free versus 45%.

AZN Price Action: AstraZeneca shares were up 0.73% at $185.78 during premarket trading on Monday, according to Benzinga Pro data.

Read Also: Goldman Sachs Says Wait With Gold Until 2027; China Isn't Listening

Image via Shutterstock

Login to unlock1,654characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.